AACR Project GENIE

AACR Project GENIE
Name	AACR Project GENIE
Established	2015
Coordinators	American Association for Cancer Research
Participants	Memorial Sloan Kettering Cancer Center; Dana‑Farber Cancer Institute; Princess Margaret Cancer Centre; Vanderbilt University Medical Center; University of California, San Francisco; British Columbia Cancer Agency; University of Toronto; Massachusetts General Hospital; Johns Hopkins Hospital; Stanford University School of Medicine
Country	United States; Canada; United Kingdom
Data types	Clinical annotations; somatic mutation calls; copy number alterations; structural variants; tumor mutational burden; limited germline annotations
Access	Controlled access via data sharing agreements; open aggregate queries

AACR Project GENIE AACR Project GENIE is a large, multi‑institutional genomic registry launched to aggregate, harmonize, and share cancer genomic and clinical data to accelerate precision oncology. Initiated by the American Association for Cancer Research, the initiative unites leading academic centers and cancer hospitals to enable translational research, biomarker discovery, and clinical trial matching across diverse tumor types. The resource emphasizes real‑world sequencing data from routine clinical care, linking molecular profiles to limited clinical outcomes to inform therapeutic decision‑making.

Background and Objectives

The project was conceived to address gaps identified by stakeholders including the American Association for Cancer Research, Memorial Sloan Kettering Cancer Center, Dana‑Farber Cancer Institute, Johns Hopkins Hospital, and Stanford University School of Medicine in harmonized, multi‑center genomic repositories that could support cross‑institutional analyses. Primary objectives included creating a federated database to capture somatic alteration frequencies, enabling comparative analyses for institutions such as Vanderbilt University Medical Center and Massachusetts General Hospital, and supporting registry‑based evidence generation for regulatory agencies like the U.S. Food and Drug Administration and guideline bodies including the National Comprehensive Cancer Network. Secondary aims encompassed informing clinical trial design at centers like Princess Margaret Cancer Centre and facilitating biomarker validation for consortia such as The Cancer Genome Atlas investigators and collaborating groups.

Data Collection and Cohorts

Contributing sites provided de‑identified, clinicogenomic data from institutional sequencing platforms including targeted panels, whole‑exome sequencing, and hybrid capture assays performed in clinical laboratories such as those at Memorial Sloan Kettering Cancer Center and Dana‑Farber Cancer Institute. Cohorts span adult and pediatric oncology populations treated at institutions like British Columbia Cancer Agency and University of California, San Francisco, covering tumor types commonly managed at Johns Hopkins Hospital and rarer entities referred to specialty centers like University of Toronto and Stanford University School of Medicine. Data elements typically include patient demographics, tumor histology classifications aligned with standards from organizations such as the World Health Organization and staging informed by societies like the American Joint Committee on Cancer, along with genomic calls for somatic single nucleotide variants, indels, copy number changes, and structural rearrangements.

Data Processing and Harmonization

A central feature has been standardized pipelines to harmonize variant annotation across heterogeneous assays, leveraging bioinformatics frameworks and nomenclatures endorsed by entities such as the Human Genome Organisation and variant interpretation guidelines influenced by the American College of Medical Genetics and Genomics. Harmonization involved mapping assay‑specific coordinates to common reference genomes and applying uniform filters for artifact reduction used in clinical genomics labs at institutions including Massachusetts General Hospital and Vanderbilt University Medical Center. Clinical ontologies and histology mapping were reconciled to enable pooled analyses comparable to efforts by the International Cancer Genome Consortium and cross‑referenced with public resources curated by groups like Broad Institute researchers.

Access, Governance, and Ethical Considerations

Governance structures involve data use agreements and institutional review oversight from contributing centers such as Memorial Sloan Kettering Cancer Center, Dana‑Farber Cancer Institute, and Princess Margaret Cancer Centre, with patient privacy protections consistent with regulatory frameworks including Health Insurance Portability and Accountability Act requirements where applicable. Access models balance open aggregate query capability with controlled access to patient‑level de‑identified datasets for approved investigators affiliated with organizations like Johns Hopkins Hospital and Stanford University School of Medicine. Ethical considerations include stewardship of incidental findings in partnership with clinical genomics programs at University of California, San Francisco and policies for equitable data sharing aligned with principles advocated by groups such as the Global Alliance for Genomics and Health.

Key Findings and Publications

Analyses leveraging the resource have characterized mutation prevalence across tumor types, identified recurrent actionable alterations corresponding to targets of therapies developed by pharmaceutical firms and evaluated in trials at centers like Massachusetts General Hospital and Dana‑Farber Cancer Institute. Publications have described patterns of tumor mutational burden, landscape studies comparing cohorts from Memorial Sloan Kettering Cancer Center and Vanderbilt University Medical Center, and case series linking genomic alterations to response signals later explored at trial sites including Johns Hopkins Hospital. Findings have been disseminated in peer‑reviewed journals and presented at meetings hosted by organizations such as the American Society of Clinical Oncology, the European Society for Medical Oncology, and the American Association for Cancer Research.

Impact on Clinical Practice and Research

The registry has informed clinical decision support tools and molecular tumor board deliberations at participating institutions such as Stanford University School of Medicine, University of Toronto, and Princess Margaret Cancer Centre, supporting variant interpretation and trial matching. It has enabled retrospective biomarker studies that influenced trial enrollment strategies run by cooperative groups and industry partners, and supported regulatory science consultations involving stakeholders including the U.S. Food and Drug Administration. By providing a comparative framework for real‑world genomic frequencies, the resource has contributed to translational research agendas pursued at the Broad Institute, Dana‑Farber Cancer Institute, and other academic centers, advancing precision oncology and collaborative data sharing models.

Category:Cancer genomics databases